Sfoglia per Rivista CANCER CHEMOTHERAPY AND PHARMACOLOGY
5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: Should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma
2006-01-01 Formica, V; Leary, A; Cunningham, D; Chua, Yj
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer
1999-01-01 Hohaus, S; Martin, S; Schneeweiss, A; Voso, Mt; Schlenk, R; Wallwiener, D; Bastert, G; Haas, R
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes
2002-01-01 Tentori, L; Portarena, I; Vernole, P; Gold, B; Graziani, G
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
2016-01-01 Zaniboni, A; Formica, V
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components
2001-01-01 Tentori, L; Portarena, I; Vernole, P; De Fabritiis, P; Madaio, R; Balduzzi, A; Roy, R; Bonmassar, E; Graziani, G
HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
2004-11-01 Palumbo, C; ALBONICI BOVE, L; Bei, R; Bocci, C; Scarpa, S; DI NARDO, P; Modesti, A
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds
1997-01-01 Alvino, E; Gilberti, S; Cantagallo, D; Massoud, R; Gatteschi, A; Tentori, L; Bonmassar, E; D'Atri, S
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).
2013-01-01 Corsello, S; Salvatori, R; Barnabei, A; DE VECCHIS, L; Marchetti, P; Torino, F
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
2013-01-01 Tentori, L; Muzi, A; Dorio, A; Dolci, S; Campolo, F; Vernole, P; Lacal, P; Praz, F; Graziani, G
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
2009-10-01 Comella, P; Lorusso, V; Maiorino, L; Casaretti, R; Cannone, M; Massidda, B; Putzu, C; Leo, S; Roselli, M; Mancarella, S; Palmeri, S; Greco, E; Vessia, G; Sandomenico, C; Franco, L
Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed
2008-04-01 Palumbo, C; Battisti, S; Carbone, D; ALBONICI BOVE, L; Alimandi, M; Bei, R; Modesti, A
Response from Drs. Formica/Zaniboni to Dr. Milano
2016-01-01 Formica, V; Zaniboni, A
Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents
2003-09-01 Vernole, P; Pepponi, R; D'Atri, S
Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents
2003-01-01 Vernole, P; Pepponi, R; D'Atri, S
Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance
2011-06-01 Kalimutho, M; Minutolo, A; Grelli, S; Formosa, A; Sancesario, G; Valentini, A; Federici, G; Bernardini, S
The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
2009-01-01 Ascione, A; Cianfriglia, M; Dupuis, M; Mallano, A; Sau, A; Pellizzari Tregno, F; Pezzola, S; Caccuri, Am
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile